Why is Australia an attractive location for conducting Phase I clinical trials?

Question

BlackTom AI · Accepted Answer

Australia’s regulatory framework for early‑phase studies is recognized as streamlined and efficient, so “Streamlined regulatory process” is the correct choice.

1) Relevant knowledge points and concepts
- Australia provides clear, established pathways for Phase I (first‑in‑human) trials (e.g., Clinical Trial Notification/Exemption approaches) with defined roles for the Therapeutic Goods Administration (TGA), Human Research Ethics Committees (HRECs), and institutional governance. 
- Sponsors benefit from internationally‑aligned Good Clinical Practice (GCP) standards, experienced investigative sites, and predictable review timelines. 
- These features reduce administrative friction and time‑to‑start compared with jurisdictions that require heavier pre‑submission dossiers or lengthier centralized review.

2) Step‑by‑step reasoning
- Phase I trials are sensitive to start‑up delays; a jurisdiction that has predictable ethics and regulatory processes speeds project timelines. 
- Australia’s model allows sponsors to work with local HRECs and the TGA under well‑documented schemes, enabling faster approvals and clear sponsor responsibilities. 
- Faster approvals and reliable site capability make Australia attractive for dosing first subjects and completing early safety and PK assessments.

3) Calculations
- No numerical calculations are required for this conceptual choice. The decision is based on comparative regulatory and operational attributes.

4) Why the correct answer is correct
- “Streamlined regulatory process” captures the principal advantage: Australia’s transparent, experienced regulatory/ethics ecosystem lowers administrative barriers and shortens time to trial initiation for Phase I studies.

5) Why other options are incorrect
- a. “High regulatory barriers” is opposite to reality; Australia’s strength is lower administrative friction for many early‑phase trials. 
- c. “High operational costs” is not a primary reason Australia is chosen; costs are often competitive versus some other developed markets. 
- d. “Limited participant pool” is incorrect because major Australian centers have access to adequate healthy volunteer and patient populations for Phase I work.

6) Conclusion
Given the established, efficient regulatory and ethics pathways in Australia, the correct answer is “Streamlined regulatory process,” which matches the provided answer.

Why is Australia an attractive location for conducting Phase I clinical trials?单项选择题

类似问题

Multiple Choice: In which of the following cases would a randomized controlled trial be required to show efficacy of a probiotic supplement?

Which phase of clinical trials primarily aims to evaluate the efficacy and optimal dose of a new treatment in patients with the target disease?

Which member of the clinical trial team is responsible for the overall conduct of the trial at a study site?

How long do Phase III clinical trials typically run?

Which clinical trial design involves assigning participants to different treatment groups, where each group receives only one treatment throughout the study?

Adverse events are difficulties that participants reported about the interventions provided in the study. These are listed in the Results section. Based on what was reported in final paragraph of the results section, select from the list below which adverse event were reported by participants.

What is the typical probability of success for a drug in Phase 1 trials ?

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单